Iron chelation in thalassemia: Time to reconsider our comfort zones

Expert Review of Hematology

Volumn 4, Issue 1, 2011, Pages 17-26

  Berdoukas, Vasilios ^a   Farmaki, Kallistheni ^b   Wood, John C ^a   Coates, Thomas ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b General Hospital of Corinth   (Greece)

Author keywords

compliance; deferasirox; deferiprone; desferrioxamine; endocrine dysfunction; iron chelation; magnetic resonance imaging; thalassemia; transfusion iron overload

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; GLUCONATE ZINC; IRON; IRON CHELATING AGENT; TACHPYRIDINE; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; ANAPHYLAXIS; ARTHRALGIA; BLOOD TRANSFUSION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CYTOPENIA; DIGESTIVE SYSTEM ULCER; EYE DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEARING DISORDER; HEART; HEART FAILURE; HEPATITIS; HUMAN; HYPOGONADISM; HYPOPHYSIS; HYPOTHYROIDISM; IMPAIRED GLUCOSE TOLERANCE; IRON BLOOD LEVEL; IRON CHELATION; IRON LIVER LEVEL; IRON OVERLOAD; LIVER; LIVER DISEASE; LIVER LEVEL; MORBIDITY; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PUBERTY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SHORT STATURE; SIDE EFFECT; SURVIVAL; SURVIVAL TIME; THALASSEMIA MAJOR;

BENZOIC ACIDS; DEFEROXAMINE; DRUG THERAPY, COMBINATION; FERRITINS; HUMANS; IRON; IRON CHELATING AGENTS; PYRIDONES; SURVIVAL ANALYSIS; THALASSEMIA; TRIAZOLES;

EID: 79951776374     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.10.74     Document Type: Review

References (92)

1. Weatherall DJ. Hemoglobinopathies worldwide: present and future. Curr. Mol. Med. 8, 592-599 (2008).
2. Delea TE, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective. Pharmacoeconomics 25, 329-342 (2007). (Pubitemid 46607383)
3. Wolman IJ, Ortolani M. Some clinical features of Cooleys anemia patients as related to transfusion schedules. Ann. NY Acad. Sci. 165, 407-414 (1969).
4. Wolman IJ. Transfusion therapy in Cooleys anemia: growth and health as related to long-range hemoglobin levels. A progress report. Ann. NY Acad. Sci. 119, 736-747 (1964).
5. Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet 2, 27-30 (1989). (Pubitemid 19158169)
6. Modell B, Letsky EA, Flynn DM, Peto R, Weatherall DJ. Survival and desferrioxamine in thalassaemia major. Br. Med. J. (Clin. Res. Ed.) 284, 1081-1084 (1982). (Pubitemid 12135972)
7. Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 355, 2051-2052 (2000). (Pubitemid 30339248)
8. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J. Cardiovasc. Magn. Reson. 10, 42 (2008).
9. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br. J. Haematol. 148, 466-475 (2010).
10. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur. Heart J. 22, 2171-2179 (2001) (Pubitemid 33139463)
11. Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood 103, 1934-1936 (2004). (Pubitemid 38268994)
12. Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2*mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 106, 1460-1465 (2005). (Pubitemid 41129616)
13. St Pierre TG, Clark PR, Chua-Anusorn W. Measurement and mapping of liver iron concentrations using magnetic resonance imaging. Ann. NY Acad. Sci. 1054, 379-385 (2005). (Pubitemid 43031045)
14. Au WY, Lam WW, Chu W, et al. A T2*magnetic resonance imaging study of pancreatic iron overload in thalassemia major. Haematologica 93, 116-119 (2008). (Pubitemid 351156159)
15. Noetzli LJ, Papudesi J, Coates TD, Wood JC. Pancreatic iron loading predicts cardiac iron loading in thalassemia major. Blood 114, 4021-4026 (2009).
16. Sparacia G, Banco A, Midiri M, Iaia A. MR imaging technique for the diagnosis of pituitary iron overload in patients with transfusion-dependent β-thalassemia major. AJNR Am. J. Neuroradiol. 19, 1905-1907 (1998). (Pubitemid 30409978)
17. Lam WW, Au WY, Chu WC, Tam S, Ha SY, Pennell DJ. One-stop measurement of iron deposition in the anterior pituitary, liver, and heart in thalassemia patients. J. Magn. Reson. Imaging. 28, 29-33 (2008). (Pubitemid 351956462)
18. Finch CA, Bellotti V, Stray S, et al. Plasma ferritin determination as a diagnostic tool. West. J. Med. 145, 657-663 (1986). (Pubitemid 17196113)
19. Kattamis C, Lagos P, Langona E. Chelation therapy and ferritin levels in patients with homozygous β-thalassemia. Prog. Clin. Biol. Res. 34, 351-359 (1979).
20. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 89, 1187-1193 (2004). (Pubitemid 39390442)
21. Aessopos A, Fragodimitri C, Karabatsos F, et al. Cardiac magnetic resonance imaging R2*assessments and analysis of historical parameters in patients with transfusion-dependent thalassemia. Haematologica 92, 131-132 (2007). (Pubitemid 46232670)
22. Tanner MA, Galanello R, Dessi C, et al. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J. Cardiovasc. Magn. Reson. 8, 543-547 (2006).
23. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N. Engl. J. Med. 331, 567-573 (1994). (Pubitemid 24265698)
24. Berdoukas V, Dakin C, Freema A, Fraser I, Aessopos A, Bohane T. Lack of correlation between iron overload cardiac dysfunction and needle liver biopsy iron concentration. Haematologica 90, 685-686 (2005). (Pubitemid 40780888)
25. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 88, 489-496 (2003). (Pubitemid 36648438)
26. Angelucci E, Muretto P, Nicolucci A, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 100, 17-21 (2002). (Pubitemid 35177422)
27. Borgna-Pignatti C, Vergine G, Lombardo T, et al. Hepatocellular carcinoma in the thalassaemia syndromes. Br. J. Haematol. 124, 114-117 (2004). (Pubitemid 38021631)
28. Adhoute X, Foucher J, Laharie D, et al. Diagnosis of liver fibrosis using FibroScan and other noninvasive methods in patients with hemochromatosis: a prospective study. Gastroenterol. Clin. Biol. 32, 180-187 (2008). (Pubitemid 351635694)
29. Barosi G, Arbustini E, Gavazzi A, Grasso M, Pucci A. Myocardial iron grading by endomyocardial biopsy. A clinico-pathologic study on iron overloaded patients. Eur. J. Haematol. 42, 382-388 (1989). (Pubitemid 19131449)
30. Olivieri NF, Koren G, Matsui D, et al. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood 79, 2741-2748 (1992).
31. Kirk P, Roughton M, Porter JB, et al. Cardiac T2*magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 120, 1961-1968 (2009).
32. Papakonstantinou O, Ladis V, Kostaridou S, et al. The pancreas in β-thalassemia major: MR imaging features and correlation with iron stores and glucose disturbances. Eur. Radiol. 17, 1535-1543 (2007). (Pubitemid 46767602)
33. Wood JC, Noetzl L, Hyderi A, Joukar M, Coates T, Mittelman S. Predicting pituitary iron and endocrine dysfunction. Ann. NY Acad. Sci. 1202, 123-128 (2010).
34. Argyropoulou MI, Kiortsis DN, Astrakas L, Metafratzi Z, Chalissos N, Efremidis SC. Liver, bone marrow, pancreas and pituitary gland iron overload in young and adult thalassemic patients: a T2 relaxometry study. Eur. Radiol. 17, 3025-3030 (2007). (Pubitemid 350142326)
35. Aessopos A, Berdoukas V, Tsironi M. The heart in transfusion dependent homozygous thalassaemia today-prediction, prevention and management. Eur. J. Haematol. 80, 93-106 (2008).
36. Barry M, Flynn DM, Letsky EA, Risdon RA. Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progress. Br. Med. J. 2, 16-20 (1974).
37. Propper RD, Cooper B, Rufo RR, et al. Continuous subcutaenous administration of deferoxamine in patients with iron overload. N. Engl. J. Med. 297, 418-423 (1977). (Pubitemid 8197453)
38. Hussain MA, Green N, Flynn DM, Hussein S, Hoffbrand AV. Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload. Lancet 2, 1278-1280 (1976).
39. Wolfe L, Olivieri N, Sallan D, et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N. Engl. J. Med. 312, 1600-1603 (1985). (Pubitemid 15062652)
40. Freeman AP, Giles RW, Berdoukas VA, Talley PA, Murray IP. Sustained normalization of cardiac function by chelation therapy in thalassaemia major. Clin. Lab. Haematol. 11, 299-307 (1989). (Pubitemid 20026864)
41. Berdoukas V, Bohane T, Tobias V, et al. Liver iron concentration and fibrosis in a cohort of transfusion-dependent patients on long-term desferrioxamine therapy. Hematol. J. 5, 572-578 (2005). (Pubitemid 40309622)
42. Tamary H, Goshen J, Carmi D, et al. Long-term intravenous deferoxamine treatment for noncompliant transfusion-dependent β-thalassemia patients. Isr. J. Med. Sci. 30, 658-664 (1994). (Pubitemid 24244971)
43. Caro JJ, Ward A, Green TC, et al. Impact of thalassemia major on patients and their families. Acta Haematol. 107, 150-157 (2002). (Pubitemid 34455079)
44. Gabutti V. Current therapy for thalassemia in Italy. Ann. NY Acad. Sci. 612, 268-274 (1990).
45. Piga A, Luzzatto L, Capalbo P, Gambotto S, Tricta F, Gabutti V. High-dose desferrioxamine as a cause of growth failure in thalassemic patients. Eur. J. Haematol. 40, 380-381 (1988).
46. Albera R, Pia F, Morra B, et al. Hearing loss and desferrioxamine in homozygous β-thalassemia. Audiology 27, 207-214 (1988).
47. Gelmi C, Borgna-Pignatti C, Franchin S, Tacchini M, Trimarchi F. Electroretinographic and visual-evoked potential abnormalities in patients with β-thalassemia major. Ophthalmologica 196, 29-34 (1988). (Pubitemid 18041342)
48. Giardina PJ, Grady RW. Chelation therapy in β-thalassemia: an optimistic update. Semin. Hematol. 38, 360-366 (2001). (Pubitemid 32995605)
49. Chan GC, Chan S, Ho PL, Ha SY. Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients. Hemoglobin 33, 352-360 (2009).
50. Chung BH, Ha SY, Chan GC, et al. Klebsiella infection in patients with thalassemia. Clin. Infect. Dis. 36, 575-579 (2003). (Pubitemid 36259561)
51. Li CK, Shing MM, Chik KW, Lee V, Yuen PM. Klebsiella pneumoniae meningitis in thalassemia major patients. Pediatr. Hematol. Oncol. 18, 229-232 (2001). (Pubitemid 32240703)
52. Adamkiewicz TV, Berkovitch M, Krishnan C, Polsinelli C, Kermack D, Olivieri NF. Infection due to Yersinia enterocolitica in a series of patients with β-thalassemia: incidence and predisposing factors. Clin. Infect. Dis. 27, 1362-1366 (1998). (Pubitemid 29242403)
53. Green NS. Yersinia infections in patients with homozygous β-thalassemia associated with iron overload and its treatment. Pediatr. Hematol. Oncol. 9, 247-254 (1992).
54. Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol. Rev. 57, 547-583 (2005). (Pubitemid 43036441)
55. Wu SF, Peng CT, Wu KH, Tsai CH. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients. Hemoglobin 30, 215-218 (2006).
56. Olivieri NF, Brittenham GM, Matsui D, et al. Iron-chelation therapy with oral deferipronein patients with thalassemia major. N. Engl. J. Med. 332, 918-922 (1995).
57. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in β-thalassemia major patients with asymptomatic myocardial siderosis. Blood 107, 3738-3744 (2006).
58. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in β-thalassaemia. Lancet 360, 516-520 (2002). (Pubitemid 35232104)
59. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine-or deferiprone-treated patients with thalassemia major. Blood 107, 3733-3737 (2006).
60. Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in β-thalassemia major. Blood 111, 583-587 (2008).
61. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br. J. Haematol. 103, 361-364 (1998). (Pubitemid 28522439)
62. Grady RW, Rachmielewitz EA, Giardina PJ. Optimising chelation therapy: combining deferiprone and deferoxamine. Blood 96, 604a (2000).
63. Maggio A, Vitrano A, Capra M, et al. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomized clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells Mol. Dis. 42, 247-251 (2009).
64. Galanello R, Kattamis A, Piga A, et al. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica 91, 1241-1243 (2006). (Pubitemid 44408435)
65. Tanner MA, Galanello R, Dessi C, et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J. Cardiovasc. Magn. Reson. 10, 12 (2008).
66. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-βlind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 115, 1876-1884 (2007). (Pubitemid 46598901)
67. Tsironi M, Deftereos S, Andriopoulos P, Farmakis D, Meletis J, Aessopos A. Reversal of heart failure in thalassemia major by combined chelation therapy: a case report. Eur. J. Haematol. 74, 84-85 (2005). (Pubitemid 40143694)
68. Tavecchia L, Masera N, Russo P, et al. Successful recovery of acute hemosiderotic heart failure in β-thalassemia major treated with a combined regimen of desferrioxamine and deferiprone. Haematologica 91(Suppl. 6), ECR19 (2006).
69. Wu KH, Chang JS, Tsai CH, Peng CT. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with β-thalassemia major. Ann. Hematol. 83, 471-473 (2004). (Pubitemid 38877974)
70. Cappellini MD, Cohen A, Piga A, et al. A Phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood 107, 3455-3462 (2006).
71. Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 95, 557-566 (2010).
72. Taher A, Cappellini MD. Update on the use of deferasirox in the management of iron overload. Ther. Clin. Risk Manag. 5, 857-868 (2009).
73. Taher A, Cappellini MD, Vichinsky E, et al. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br. J. Haematol. 147, 752-759 (2009).
74. Taher A, El-Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study. Eur. J. Haematol. 82, 458-465 (2009).
75. Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia. Blood 115, 2364-2371 (2010).
76. Wood JC, Kang BP, Thompson A, et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood 116(4), 537-543 (2010).
77. Jetsrisuparb A, Komvilaisak P, Wiangnon S, Jetsrisuparb C. Retrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: first evidence of more than 2 years. J. Pediatr. Hematol. Oncol. 32(5), 400-403 (2010).
78. Balocco M, Carrara P, Pinto V, Forni GL. Daily alternating deferasirox and deferiprone therapy for hard-to-chelate β-thalassemia major patients. Am. J. Hematol. 85, 460-461 (2010).
79. Berdoukas V, Carson S, Nord A, et al. Combining two orally active iron chelators for thalassemia. Ann. Hematol. 89, 1177-1178 (2010).
80. Telfer P, Coen PG, Christou S, et al. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica 91, 1187-1192 (2006). (Pubitemid 44408428)
81. Maggio A, Vitrano A, Capra M, et al. Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial. Br. J. Haematol. 145, 245-254 (2009).
82. Wood JC. Cardiac iron across different transfusion-dependent diseases. Blood Rev. 22(Suppl. 2), S14-S21 (2008).
83. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of β-thalassemia major in North America. Blood 104, 34-39 (2004). (Pubitemid 38879833)
84. Barratt PS, Toogood IR. Hearing loss attributed to desferrioxamine in patients with β-thalassaemia major. Med. J. Aust. 147, 177-179 (1987). (Pubitemid 18047066)
85. Schindlery C. Hearing loss attributed to desferrioxamine in patients with β-thalassaemia major. Med. J. Aust. 148, 662-663 (1988).
86. Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 102, 2670-2677 (2003). (Pubitemid 37193611)
87. Daar S, Pathare A, Nick H, et al. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia. Eur. J. Haematol. 82, 454-457 (2009).
88. Pootrakul P, Breuer W, Sametband M, Sirankapracha P, Hershko C, Cabantchik ZI. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded β-thalassemia/HbE patients treated with an oral chelator. Blood 104, 1504-1510 (2004). (Pubitemid 39166531)
89. Walter PB, Macklin EA, Porter J, et al. Inflammation and oxidant-stress in β-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica 93, 817-825 (2008). (Pubitemid 351821718)
90. Flexner JM. Hemochromatosis: diagnosis and treatment. Compr. Ther. 17, 7-9 (1991).
91. Hramiak IM, Finegood DT, Adams PC. Factors affecting glucose tolerance in hereditary hemochromatosis. Clin. Invest. Med. 20, 110-118 (1997). (Pubitemid 27168377)
92. FBS0701 program www. ferrokin. com/fbs0701-program. Html